Substance / Medication

Tetanus immunoglobulin

Overview

Active Ingredient
tetanus immune globulin
RxNorm CUI
1727875

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Incremental costs of treating tetanus with intrathecal antitetanus immunoglobulin.
Miranda-Filho Demócrito B, Ximenes Ricardo A A, Siqueira-Filha Noêmia T et al. · Trop Med Int Health · 2013
PMID: 23461581RCT
Collaborative study for the validation of alternative in vitro potency assays for human tetanus immunoglobulin.
Gross S, Janssen S W J, de Vries B et al. · Pharmeur Bio Sci Notes · 2009
PMID: 20144449Observational
Intrathecal tetanus immunoglobulins in the management of tetanus.
Geeta M G, Krishnakumar P, Mathews Lulu · Indian J Pediatr · 2007
PMID: 17264452Observational
Successful management of generalized tetanus in a 12-year old girl without anti-tetanus immunoglobulins: a case report.
Muhelo Arlindo, Zita Ahivaldino, Seni Amir et al. · Oxf Med Case Reports · 2022
PMID: 36176952Case ReportFull text (PMC)
Progressive localized tetanus in patient with inadequate human tetanus immunoglobulin therapy.
Licindo Daniel, Putra Evan Matthew, Rombetasik Medianto et al. · IDCases · 2021
PMID: 34026537Case ReportFull text (PMC)
Collaborative study for the establishment of Ph. Eur. Biological Reference Preparation for Human tetanus immunoglobulin batch 2.
Stickings P, Tierney R, Hockley J et al. · Pharmeur Bio Sci Notes · 2024
PMID: 38252512Other
Seroprevalence of Diphtheria and Tetanus Immunoglobulin G among the General Health Population in Guangzhou, China.
He Qing, Wu Yejian, Hou Shuiping et al. · Vaccines (Basel) · 2024
PMID: 38675763OtherFull text (PMC)
Immunoaffinity chromatography for the preparation of equine tetanus immunoglobulin F(ab')for enhanced safety and efficacy.
Gao Xingyue, Liu Jiao, Xu Kai et al. · J Chromatogr B Analyt Technol Biomed Life Sci · 2025
PMID: 40286483Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tetanus immunoglobulin (substance)
SNOMED CT
425682001
UMLS CUI
C4048265
RxNorm CUI
1727875

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.